Skip to main content
Figure 3 | Cancer Imaging

Figure 3

From: Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab

Figure 3

Relationship between perfusion parameters and progression-free survival (PFS). A) Pre-treatment, atlas-defined hypervascular volume (Log-rank, P = 0.0027). B) Post-treatment, atlas-defined hypervascular volume (Log-rank, P = 0.0025). C) Change in atlas-defined hypervascular volume (Log-rank, P = 0.0672). D) Pre-treatment, mean standardized CBV (black lines; Log-rank, P = 0.9704) and maximum standardized CBV (gray lines; Log-rank, P = 0.7228). E) Post-treatment, mean standardized CBV (black lines; Log-rank, P = 0.3740) and maximum standardized CBV (gray lines; Log-rank, P = 0.2022). F) Change in mean standardized CBV (black lines; Log-rank, P = 0.1209) and maximum standardized CBV (gray lines; Log-rank, P = 0.0316).

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us